Physician profile
Robert J Pohl
NPI 1205182565
$1,247.00
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $628 · 2023: $130 · 2024: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $260.51 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.61 | 2021-2023 | Lifevest |
| Boston Scientific Corporation | $135.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $107.34 | 2021-2022 | |
| Amgen INC. | $106.05 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $99.37 | 2023-2024 | Inpefa |
| Philips North America LLC | $71.77 | 2023-2024 | (Ck4) Mcot, (Ck7) Extended Holter |
| Astrazeneca Pharmaceuticals LP | $52.69 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $41.35 | 2022 | |
| Abbott Laboratories | $40.00 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $34.01 | 2022 | |
| Cvrx, INC. | $32.46 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.00 | 2022 | |
| Esperion Therapeutics, INC. | $22.07 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $19.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.